413 related articles for article (PubMed ID: 24866272)
1. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer.
Bu H; He X; Zhang Z; Yin Q; Yu H; Li Y
Int J Pharm; 2014 Aug; 471(1-2):206-13. PubMed ID: 24866272
[TBL] [Abstract][Full Text] [Related]
2. Co-encapsulation of paclitaxel and baicalein in nanoemulsions to overcome multidrug resistance via oxidative stress augmentation and P-glycoprotein inhibition.
Meng L; Xia X; Yang Y; Ye J; Dong W; Ma P; Jin Y; Liu Y
Int J Pharm; 2016 Nov; 513(1-2):8-16. PubMed ID: 27596118
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel nanosuspension coated with P-gp inhibitory surfactants: II. Ability to reverse the drug-resistance of H460 human lung cancer cells.
Gao L; Liu G; Ma J; Wang X; Wang F; Wang H; Sun J
Colloids Surf B Biointerfaces; 2014 May; 117():122-7. PubMed ID: 24632038
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-loaded N-octyl-O-sulfate chitosan micelles for superior cancer therapeutic efficacy and overcoming drug resistance.
Jin X; Mo R; Ding Y; Zheng W; Zhang C
Mol Pharm; 2014 Jan; 11(1):145-57. PubMed ID: 24261922
[TBL] [Abstract][Full Text] [Related]
5. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
6. D-α-tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells.
Bao Y; Guo Y; Zhuang X; Li D; Cheng B; Tan S; Zhang Z
Mol Pharm; 2014 Sep; 11(9):3196-209. PubMed ID: 25102234
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic vitamin E nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating Th1 and Th2 immune response.
Pawar VK; Panchal SB; Singh Y; Meher JG; Sharma K; Singh P; Bora HK; Singh A; Datta D; Chourasia MK
J Control Release; 2014 Dec; 196():295-306. PubMed ID: 25459427
[TBL] [Abstract][Full Text] [Related]
8. Vitamin E derivative-based multifunctional nanoemulsions for overcoming multidrug resistance in cancer.
Zheng N; Gao Y; Ji H; Wu L; Qi X; Liu X; Tang J
J Drug Target; 2016 Aug; 24(7):663-9. PubMed ID: 26710274
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis.
Hu Y; Zhang K; Zhu X; Zheng X; Wang C; Niu X; Jiang T; Ji X; Zhao W; Pang L; Qi Y; Li F; Li L; Xu Z; Gu W; Zou H
Int J Nanomedicine; 2021; 16():2173-2186. PubMed ID: 33758505
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors.
Yoshizawa Y; Ogawara K; Kimura T; Higaki K
Eur J Pharm Sci; 2014 Oct; 62():274-80. PubMed ID: 24956463
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
12. Controlled release and reversal of multidrug resistance by co-encapsulation of paclitaxel and verapamil in solid lipid nanoparticles.
Baek JS; Cho CW
Int J Pharm; 2015 Jan; 478(2):617-24. PubMed ID: 25510604
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Assanhou AG; Li W; Zhang L; Xue L; Kong L; Sun H; Mo R; Zhang C
Biomaterials; 2015 Dec; 73():284-95. PubMed ID: 26426537
[TBL] [Abstract][Full Text] [Related]
14. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Baek JS; Cho CW
J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
[TBL] [Abstract][Full Text] [Related]
15. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
16. Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo.
Lu J; Chuan X; Zhang H; Dai W; Wang X; Wang X; Zhang Q
Int J Pharm; 2014 Aug; 471(1-2):525-35. PubMed ID: 24858391
[TBL] [Abstract][Full Text] [Related]
17. Redox-sensitive mPEG-SS-PTX/TPGS mixed micelles: An efficient drug delivery system for overcoming multidrug resistance.
Zhao D; Zhang H; Yang S; He W; Luan Y
Int J Pharm; 2016 Dec; 515(1-2):281-292. PubMed ID: 27746331
[TBL] [Abstract][Full Text] [Related]
18. Fmoc-conjugated PEG-vitamin E2 micelles for tumor-targeted delivery of paclitaxel: enhanced drug-carrier interaction and loading capacity.
Zhang Y; Huang Y; Zhao W; Lu J; Zhang P; Zhang X; Li J; Gao X; Venkataramanan R; Li S
AAPS J; 2014 Nov; 16(6):1282-91. PubMed ID: 25193267
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance.
Jia L; Li Z; Shen J; Zheng D; Tian X; Guo H; Chang P
Int J Pharm; 2015 Jul; 489(1-2):318-30. PubMed ID: 25956050
[TBL] [Abstract][Full Text] [Related]
20. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
